Tesamorelin
10mg vial
A$ 196Rp 2.200.000
A compound that prompts the body to release its own growth hormone in a natural pattern. Studied for reduction of deep abdominal fat, improvements in body composition, and metabolic support in adults.
Compound overview
What it is
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland and triggers the release of endogenous growth hormone in a pulsatile, physiological pattern — preserving the natural feedback mechanism that synthetic exogenous GH bypasses. This means IGF-1 rises, GH rises, but the body's own regulatory signals remain intact.
Visceral adipose tissue (VAT) — the deep abdominal fat associated with metabolic disease — begins to reduce. Lean mass is preserved or increased. Lipid profiles often improve. Sleep quality and recovery may improve as GH pulsatility is restored. IGF-1 levels rise and can be monitored to gauge response.
Studied outcomes
- Significant reduction in visceral adipose tissue in HIV lipodystrophy and general population studies
- Improved IGF-1 levels reflecting pituitary response
- Reduction in triglycerides and improvement in lipid ratios
- Preservation and modest increase in lean body mass
- Improvements in cognitive function in studies with older adults
Suitability
Who it's for
- Visceral abdominal fat reduction — particularly deep belly fat resistant to diet
- Body recomposition alongside GLP-1 agonists or caloric restriction
- Metabolic support in GH-deficient adults
- Anti-ageing and longevity protocols targeting body composition
Who should avoid it
- Active malignancy or history of malignancy — GH elevation is contraindicated
- Pregnancy
- Pituitary tumour or damage
- Uncontrolled diabetes — monitor glucose closely if diabetic
Dosing guidance
Protocol guidance
Frequency
Once daily subcutaneous injection
Cycle length
12–26 weeks; VAT reduction is progressive
Route
Subcutaneous injection (abdomen preferred)
Timing
Before bed on an empty stomach to align with natural overnight GH pulse
Safety
Contraindications & cautions
- Monitor IGF-1 levels — maintain within physiological range
- Water retention and peripheral oedema may occur at initiation
- Joint aches (arthralgia) reported — typically dose-dependent and transient
- May worsen insulin resistance transiently — monitor glucose in metabolic clients
- Not a substitute for exogenous GH deficiency treatment under endocrinology care
Stacking
Pairs well with
Targets visceral fat through different mechanisms — powerful combination for metabolic recomposition
Stacking GHRH (tesamorelin) with a GHRP (ipamorelin) amplifies GH pulse amplitude — use under guidance
Complements metabolic and body composition goals through insulin sensitivity improvement
Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.